Modeling the Potential Impact of the 2014 American Academy of Pediatrics Respiratory Syncytial Virus Prophylaxis Guidance on Preterm Infant RSV Outcomes

Eitemau Tebyg

• The 2014–2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States
  gan: Kong, Amanda M., et al.
  Cyhoeddwyd: (2018)
• Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012–2016
  gan: Goldstein, Mitchell, et al.
  Cyhoeddwyd: (2018)
• Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics
  gan: Krilov, Leonard R., et al.
  Cyhoeddwyd: (2020)
• Impact of the 2014 American Academy of Pediatrics Policy on RSV Hospitalization in Preterm Infants in the United States
  gan: Goldstein, Mitchell, et al.
  Cyhoeddwyd: (2021)
• Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants
  gan: Shahabi, Ahva, et al.
  Cyhoeddwyd: (2017)